NICE reverses earlier decision to support use of RoActemra in giant cell arteritis.- Roche/Chugai.
The National Institute of Health and Care Excellence has given its support for the use of RoActemra (tocilizumab) from Roche/Chugai, for the treatment of eligible patients with giant cell arteritis (GCA). In draft guidelines published in November, RoActemra was initially rejected after the appraisal committee pointed to substantial uncertainties in how long patients would need to receive the therapy and the long-term benefits.
According to data from the GiACTA clinical trial, tocilizumab in combination with a tailored dose of steroids improved long-term disease control, reduced and delayed the risk of disease flare, and reduced the total dose of steroids required. Final guidance is expected towards the end of March 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins